title: Preclinical testing of virotherapeutics for primary and secondary tumors of the liver.
abstract: Virotherapy offers a new treatment strategy using oncolytic viruses as self-replicating, tumor-specific agents, which destroy tumors during their natural lytic replication process. To study potential oncolytic viruses, cell culture experiments give basic information about the lytic potential of a virus, measured as cell lysis or decreased viability. For further analysis, animal models are usually employed. As these in vivo experiments are often performed in immunocompromised animals, results have to be interpreted with caution. Therefore, to obtain deeper information of the oncolytic action of specific viruses in a patient's individual context we established a test platform based on human primary tissue slices. In this three-dimensional model, we observed a preferential tumor infection and the penetration of oncolytic measles vaccine virus into deeper cell layers of tumor tissues, which is an essential feature of an effective oncolytic virus.
authors: Department of Gastroenterology & Hepatology, Medical University Hospital, Tuebingen, Germany.
authors: Martina
authors: M
authors: Zimmermann
authors: Timo
authors: T
authors: Weiland
authors: Michael
authors: M
authors: Bitzer
authors: Ulrich M
authors: UM
authors: Lauer
mesh_terms: D045744:Cell Line, Tumor; D004353:Drug Evaluation, Preclinical; D017930:Genes, Reporter; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000235:genetics; D056945:Hep G2 Cells; D006801:Humans; D008113:Liver Neoplasms / Q000628:therapy*; D008867:Microtomy / Q000379:methods; D050130:Oncolytic Virotherapy; D050504:Oncolytic Viruses / Q000235:genetics; D014407:Tumor Cells, Cultured; D014616:Vaccinia virus / Q000235:genetics